<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01494805</url>
  </required_header>
  <id_info>
    <org_study_id>2008-135</org_study_id>
    <nct_id>NCT01494805</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of rAAV.sFlt-1 in Patients With Exudative Age-Related Macular Degeneration</brief_title>
  <acronym>AMD</acronym>
  <official_title>A Phase I/II Controlled Dose-escalating Trial to Establish the Baseline Safety and Efficacy of a Single Subretinal Injection of rAAV.sFlt-1 Into Eyes of Patients With Exudative Age-related Macular Degeneration (AMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lions Eye Institute, Perth, Western Australia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Adverum Biotechnologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lions Eye Institute, Perth, Western Australia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will involve approximately 40 subjects aged 55 or above who have exudative
      age-related macular degeneration (wet AMD). Patients will be randomized to receive one of two
      doses of rAAV.sFlt-1 or assigned to the control group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A new treatment for exudative age-related macular degeneration (wet AMD) is being
      investigated. The purpose of this Phase I/II clinical research study is to examine the
      baseline safety and efficacy of an experimental study drug to treat a complication of the
      disease which leads to vision loss. The name of the study drug is rAAV.sFlt-1.

      This experimental study uses a non-pathogenic virus to express a therapeutic protein within
      the eye. The therapeutic diminishes the growth of abnormal blood vessels under the retina.
      The duration of effect is thought to be long-term (years) following a single administration.

      The clinical research study will look at the baseline safety and efficacy of a single
      injection of rAAV.sFlt-1 injected directly into the eye.

      Approximately forty (40) subjects will participate in Australia. The primary endpoint of the
      study is at one month, with extended follow up for 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2011</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>No sign of unresolved ophthalmic complications, toxicity or systemic complications as measured by laboratory tests from 1 month post injection</measure>
    <time_frame>Primary endpoint at 1 month</time_frame>
    <description>Ocular examination:
Ocular inflammation
Intraocular pressure
Visual acuity
Retinal bleeding
Abnormal laboratory data</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maintenance or improvement of vision without the necessity of ranibizumab re-injections</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Best-corrected visual acuity
CNV lesion
Foveal thickness</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Macular Degeneration</condition>
  <condition>Age-related Maculopathies</condition>
  <condition>Age-related Maculopathy</condition>
  <condition>Maculopathies,Age-related</condition>
  <condition>Maculopathy,Age-related</condition>
  <condition>Retinal Degeneration</condition>
  <condition>Retinal Neovascularization</condition>
  <condition>Eye Diseases</condition>
  <arm_group>
    <arm_group_label>Low Dose rAAV.sFlt-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose rAAV.sFlt-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control - ranibizumab only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rAAV.sFlt-1</intervention_name>
    <description>1 x 10^10 vector genomes (vg) rAAV.sFlt-1, delivered by subretinal injection</description>
    <arm_group_label>Low Dose rAAV.sFlt-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rAAV.sFlt-1</intervention_name>
    <description>1 x 10^11 vector genomes (vg) rAAV.sFlt-1, delivered by subretinal injection</description>
    <arm_group_label>High Dose rAAV.sFlt-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control (ranibizumab alone)</intervention_name>
    <description>Patients will not receive rAAV.sFlt-1, but will be eligible for retreatment with ranibizumab (Lucentis).</description>
    <arm_group_label>Control - ranibizumab only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than or equal to 55 years;

          -  Subfoveal CNV secondary to AMD and with best corrected visual acuity of 3/60 - 6/9
             with 6/60 or better in the other eye;

          -  Fluorescein angiogram of the study eye must show evidence of a leaking subfoveal
             choroidal neovascular lesion, or CNV currently under active management with anti-VEGF
             therapy;

          -  Must be a candidate for anti-VEGF intravitreal injections;

          -  No previous retinal treatment of photodynamic therapy or laser;

          -  Able to provide informed consent;

          -  Able to comply with protocol requirements, including follow-up visits.

        Exclusion Criteria:

          -  Liver enzymes &gt; 2 X upper limit of normal;

          -  Any prior treatment for AMD in the study / control eye, excluding anti-VEGF
             injections;

          -  Extensive sub-foveal scarring, extensive geographic atrophy, or thick subretinal blood
             in the study eye as determined by the investigator;

          -  Significant retinal disease other than sub-foveal CNV AMD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian Constable, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lions Eye Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lions Eye Institute</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2011</study_first_submitted>
  <study_first_submitted_qc>December 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2011</study_first_posted>
  <last_update_submitted>August 30, 2017</last_update_submitted>
  <last_update_submitted_qc>August 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lions Eye Institute, Perth, Western Australia</investigator_affiliation>
    <investigator_full_name>Prof. P. Elizabeth Rakoczy</investigator_full_name>
    <investigator_title>Principal Scientific Investigator</investigator_title>
  </responsible_party>
  <keyword>Age-related Macular Degeneration</keyword>
  <keyword>AAV</keyword>
  <keyword>AMD</keyword>
  <keyword>Wet AMD</keyword>
  <keyword>Neovascular AMD</keyword>
  <keyword>Gene Therapy</keyword>
  <keyword>Ocular</keyword>
  <keyword>Ocular Gene Therapy</keyword>
  <keyword>Eye diseases</keyword>
  <keyword>Macular Degeneration</keyword>
  <keyword>Retinal Degeneration</keyword>
  <keyword>Retinal Neovascularization</keyword>
  <keyword>Wet Macular Degeneration</keyword>
  <keyword>Retinal Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
    <mesh_term>Retinal Degeneration</mesh_term>
    <mesh_term>Retinal Neovascularization</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

